INTRODUCTION
Mediastinal B-cell lymphomas present in the mediastinum of young patients and are mostly represented by nodular sclerosis Hodgkin lymphoma (NSHL) and primary mediastinal Bcell lymphoma (PMBL) [1] [2] [3] . The most recent World Health Organization (WHO) classification of lymphoid tissues recognized mediastinal gray zone lymphoma (MGZL), a rare lymphoma with features intermediate between PMBL and NSHL, as a new pathological entity [3] [4] [5] . Historically, these cases were often included in series of Hodgkin-like anaplastic large cell lymphoma, which was a heterogeneous group [6] [7] [8] .
The clinical characteristics and treatment of MGZL have yet to be defined due to its recent identification and rarity. NSHL and PMBL have both overlapping and distinct clinical features, raising the question of where MGZL lies within the pathological and clinical spectrum of mediastinal B-cell lymphomas. Therapeutically, the Hodgkin-like pathological features of MGZL suggest they should be treated like Hodgkin lymphoma, whereas the strong expression of the CD20 B-cell protein by most MGZL, a feature of PMBL but not NSHL, suggests they should be treated with rituximab-based regimens like PMBL.
As a group, mediastinal B-cell lymphomas are hypothesized to derive from a thymic Bcell 2, 4, 7, 9 . A significant proportion of PMBL and NSHL cases have amplification of the JAK2/PDL2 locus, which has also been reported in MGZL 9 . PMBL and NSHL also have overlapping gene expression profiles, indicating that they lie along a pathobiological continuum 2 .
MGZL has been described as the "missing link" between NSHL and PMBL 4 . We undertook a study of untreated MGZL to describe its clinical outcome with the infusional dose-adjusted immuno-chemotherapy regimen, DA-EPOCH-R, an effective treatment for PMBL, and to describe its biological characteristics 10 .
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PATIENTS AND METHODS

Study Design and Treatment
Twenty-four patients with untreated MGZL were prospectively enrolled between November 1999 and February 2013 on a study of DA-EPOCH-R at the National Cancer Institute.
Due to the recent recognition of MGZL as a distinct entity by our center in 2004, we amended our prospective study of DA-EPOCH-R in PMBL to add a separate cohort for MGZL. All but three patients were enrolled after this date. Objectives included event-free and overall survival, and immunohistochemical analysis. Pathology was confirmed by SP or ESJ according to WHO criteria 3 . Eligibility included all disease stages and performance status, negative test for Human immunodeficiency virus and pregnancy, and adequate organ function unless due to involvement by lymphoma. Evaluation included standard blood tests, whole body computed tomography (CT) and bone marrow biopsy. DA-EPOCH-R was administered as previously described 11, 12 . Disease sites were evaluated by CT scan after cycle 4 and 6 using standard response criteria 13, 14 . The
Institutional Review Board (IRB) approved the study and all patients provided consent in accordance with the Declaration of Helsinki. The trial was registered at ClinicalTrials.Gov (NCT00001337). 
FDG-PET-CT Scan Evaluation
To assess if there was disease at the end of treatment, patients with a residual mediastinal mass underwent 18-fluorodeoxyglucose positron emission tomography-computerized tomography (FDG-PET) scans. One patient who was treated early in the series received a gallium scan.
Patients with standard uptake values (SUV) above the mediastinal blood pool received repeat scans at approximately 6-week intervals until they normalized or stabilized. Patients with significantly worsening FDG-PET abnormalities underwent a biopsy in most cases to assess the presence of disease. FDG-PET scans were not repeated in patients with negative post-treatment scans. The FDG-PET scans were scored according to the 5-point Deauville scoring system with a score of 1-3 and 4-5 considered negative and positive, respectively, for disease 15, 16 . Patients diagnosed with disease after DA-EPOCH-R received radiotherapy and were classified as events.
Immunohistochemical Analysis
Immunohistochemistry (IHC) was performed on formalin-fixed, paraffin-embedded tissue sections and included CD20, CD3, CD79a, PAX-5, OCT-2, Bob-1, BCL-6, CD68 and Dendritic
For personal use only. on April 20, 2017 . by guest www.bloodjournal.org From Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin (DC-SIGN). For DC-SIGN, tissue sections underwent deparaffinization and rehydration followed by antigen retrieval using low pH Dako Target retrieval solution (Dako, Carpinteria, California) in a microwave. The slides were incubated with primary antibody (1:100 dilution) for 2 hours. As detection system "IView DAB detection kit" (Ventana Medical Systems, Tucson, Arizona) was used. The other IHC stains were performed as previously described 9 . Positive controls were run with each set of slides and showed appropriate staining patterns. 
Comparison to Primary Mediastinal B-cell Lymphoma
We compared the MGZL cases to a cohort of untreated patients with PMBL who were prospectively treated with DA-EPOCH-R. Patient eligibility was identical for both groups except patients with PMBL were required to have a mediastinal mass at least 5 cm. Treatment and follow-up were identical in both groups. The clinical outcome of patients with PMBL was
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Statistical Analysis
Overall (OS) survival was calculated from on-study date until death or last follow-up and event-free survival (EFS) was calculated from on-study date until progression, radiotherapy, death or last follow-up. The probabilities of OS and EFS were determined by the Kaplan-Meier method 18 . The significance of the difference between pairs of Kaplan-Meier curves was determined by an asymptotic or exact log-rank test as appropriate. In general, p-values are unadjusted for multiple comparisons due to being pre-specified or exploratory. However, when 
RESULTS
Patient Characteristics and Tumor Pathology
Twenty-four patients were enrolled ( Table 1) . The median (range) patient age was 33 years (14-59) and 63% were male. Forty-six percent of patients had a mediastinal mass over 10 (Table 1) . While the neoplastic cells from all cases showed some degree of CD20 expression, 71% had strong-diffuse staining on all the malignant cells ( Table 1) .
As shown in Table 1 , the neoplastic cells in 86% of tested cases also expressed the germinal center transcription factor, BCL-6. CD30 and CD15, which are typically expressed by the neoplastic cells in NSHL, were expressed by 100% and 54% of the MGZL cases, respectively ( Figure 2B ). In most cases, the malignant cells showed robust CD30 staining, while CD15 intensity was variable.
Patient Outcome
All patients responded with 19 complete and 5 partial remissions. Nine patients were diagnosed with active disease at a median (range) of 3 months (range: 1-6) after completing therapy. Presence of disease was diagnosed by biopsy in seven cases and by progressive disease on scans in two cases. Based on PET-CT evaluation showing disease limited to the mediastinal area, all nine patients received involved field salvage radiotherapy and four are in continuous remission at 3, 73, 91 and 128 months. At the median follow-up of 59 months (range 7-142), the EFS and OS was 62% and 74%, respectively ( Figure 1A, 1B) .
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Toxicity was assessed on all 145 cycles of DA-EPOCH-R. The ANC pharmacodynamic target of < 500 cells/mm 3 was achieved on 53% of cycles, with infrequent ANC < 100 cells/mm 3 (9%) and thrombocytopenia < 25,000/mm 3 (2%) Fever and neutropenia occurred on 12% of cycles. Grade 3 or higher non-hematopoietic toxicities including ileus and neurosensory occurred in < 4% of patients and were similar to prior reports 10 . There were no treatment related deaths.
Clinical and Molecular Prognostic Markers
The overlapping features of MGZL with PMBL and NSHL suggest they may share prognostic features. Due to the small sample size and absence of a validation cohort, our analyses are exploratory and hypothesis generating. We first analyzed the clinical International Prognostic Index, developed for DLBCL, and the International Prognostic Score, developed for
Hodgkin lymphoma, as well as tumor mass size, and found no associations with EFS or OS in MGZL 19, 20 . Based on our finding of reduced peripheral blood lymphocytes in MGZL, which is prognostic in Hodgkin lymphoma, we analyzed the effect on EFS and OS. We assessed the outcome of patients with ALC above and below the median of 880 cells/µl and observed a
of 83% and 42% (p=0.038), respectively, and OS of 100% and 52% (p=0.028) ( Figure 1C and 1D Figure 1E and 1F) .
The association of a Hodgkin-like microenvironment and poor outcome in MGZL raised the hypothesis that a predominant HL-like morphology and/or phenotype would also be associated with a worse outcome. To address this question, we first looked at the association between the predominant morphology and EFS and OS. Contrary to our hypothesis, there was a significant trend between the presence of a predominant PMBL-like morphology and lower EFS (p=0.025) but a weaker trend with respect to OS (p=0.21). Additionally, the intensity of CD20 staining on the malignant MGZL cells was not associated with outcome. In contrast, CD15
staining was associated with outcome. To provide a quantitative estimate of CD15 staining, cases were scored in quartiles. We analyzed two cut off-points for CD15 staining and outcome and identified a preferred cutoff between 0-2 versus 3-4, which showed an EFS of 74% and 38% (p=0.078 unadjusted; p=0.16 adjusted), respectively, and an OS of 93% and 38% (p=0.016 unadjusted; p=0.032 adjusted) at 3-years, indicating that robust expression of CD15 identifies a poor prognosis group in MGZL ( Figure 1G and 1H). Notably there was no difference in the intensity or frequency of CD15 staining between PMBL-like and Hodgkin-like MGZL, indicating that the prognostic effect of CD15 was unrelated to the predominant morphology
Comparison of MGZL and PMBL
Due to the high malignant cell expression of CD20 MGZL, suggesting it is more similar to an aggressive B-cell lymphoma, we were interested in comparing MGZL to PMBL patients enrolled on the same DA-EPOCH-R protocol, albeit in a separate cohort (Table 1) 10 .
Interestingly, the MGZL patients were significantly less likely to have an elevated LDH, extranodal disease or pleural or pericardial effusions and more likely to be male, clinical characteristics more frequent in massive mediastinal NSHL 23 . Additionally, MGZL cases were significantly more likely to express CD30 and CD15, phenotypic hallmarks of NSHL, but commonly had strong-diffuse CD20 expression, which is not found in NSHL. Clinically, patients with MGZL had a significantly worse EFS and OS compared to our recently published series of 51 patients with PMBL who received identical treatment 10 . With a median follow-up of 5-years, patients with MGZL compared to PMBL achieved a significantly lower EFS (62% versus 93%; p=0.0005) and OS (74% versus 97%; p=0.0012), respectively ( Figure 3A and 3B).
Expectedly, due to the low rate of treatment failure in PMBL, none of the biomarkers of outcome in MGZL including ALC were prognostic in PMBL.
DISCUSSION
We present the first prospective study of MGZL and describe its clinical and immunophenotypic characteristics and treatment outcome. MGZL shares clinical characteristics with PMBL and NSHL including young age and bulky mediastinal masses, but more like mediastinal NSHL, it has a male predominance, and a lower frequency of elevated LDH, extranodal disease and effusions 10, 23 . Clinically, 62% of patients achieved continuous complete remissions with DA-EPOCH-R, indicating it is an effective treatment. Furthermore, among the 9 patients who failed to achieve a durable remission, 4 (44%) were salvaged with involved field radiation alone and are in continuous remission. The remaining 5 patients were aggressively treated with salvage chemotherapy and/or allogeneic transplant and all died of disease, While our results are promising compared to standard HL-based chemotherapy plus radiation in bulky NSHL, in which over 30% of patients progress, we cannot rigorously determine if DA-EPOCH-R is optimal treatment for MGZL given the limited number of cases and absent a randomized study design 23, 25 . To help address the question of therapeutic strategy, it is useful to review the treatment outcome of Hodgkin-like anaplastic large cell lymphoma (HL-ALCL), which historically included some cases that might be considered MGZL today 3 . Zinzani et al reported the largest prospective series of HL-ALCL, but that series specifically excluded tumors with B-cell markers 8 . In that study, patients were randomized to receive either MACOP-B or ABVD to assess if these "borderline" tumors should be treated as aggressive high-grade non-Hodgkin lymphomas or Hodgkin lymphomas; 85% of patients had a mediastinal mass and patients with bulky tumors received consolidation radiation therapy. The relapse-free survival was 94% and 92% at 32 months for the two arms, respectively, indicating both treatment approaches were equally effective when combined with radiation therapy in most cases. While this series likely did not include cases we would classify as MGZL, as CD20 was an exclusion criterion, this study provides cogent evidence that histologically "borderline" tumors are not advantaged by the use of HL-based treatments.
A recent abstract from Evens et al suggests that gray zone lymphomas (GZL) have a relatively poor outcome compared to other aggressive B-cell lymphomas 26, 27 . In this study of 96 patients, 44% had mediastinal masses, suggesting a diagnosis of MGZL, while 56% had non-MGZL, which is not the same disease. At a median follow-up of approximately 2-years, the progression-free (PFS) and survival were 41% and 84%, respectively for all patients, and the outcome was similar in patients with MGZL and non-MGZL, as well as in patients who received non-HL-based or HL-based regimens. These studies are consistent with our results that show MGZL has a poorer outcome, which is likely due to higher drug resistance and not to the use of a non-HL-based treatment. Nonetheless, DA-EPOCH-R alone produced durable remissions in most patients indicating it is an effective treatment for these relatively resistant lymphomas. 
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